Oncotelic CEO buys 335,759 shares in open market

Q: How many Oncotelic (OTLC) shares did the CEO buy and at what prices?

Vuong Trieu purchased 96,000 shares at $0.05 per share on June 15, 2026 and 239,759 shares at $0.0446 per share on June 17, 2026. Both were open-market purchases of common stock.

Q: What indirect Oncotelic (OTLC) holdings related to the CEO are disclosed?

The filing lists indirect ownership of 6,872,529 shares of common stock held by his spouse and 16,780,384 shares held through Autotelic Inc. These entries show additional exposure to Oncotelic beyond his directly owned shares.

Q: Were the Oncotelic (OTLC) CEO’s transactions open-market purchases?

Yes. The Form 4 classifies both transactions as open-market purchases of common stock, with transaction code “P” and footnote disclosure stating they were bought from the open market at per-share prices of $0.05 and $0.0446.

Oncotelic Therapeutics, Inc. Chairman and CEO Vuong Trieu reported open-market purchases of company common stock.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Oncotelic Therapeutics, Inc. Chairman and CEO Vuong Trieu reported open-market purchases of company common stock. On June 15, 2026, he bought 96,000 shares at $0.05 per share, and on June 17, 2026, he bought 239,759 shares at $0.0446 per share.

After these transactions, his directly held stake is reported as 93,629,319 shares of common stock. The filing also lists indirect holdings of 6,872,529 shares held by his spouse and 16,780,384 shares held through Autotelic Inc., providing a view of both his direct and related-entity ownership.

Insider Trade Summary

Net Buyer: 335,759 shares

Net Buy 4 txns

Insider Trieu Vuong

Role CHAIRMAN AND CEO

Bought 335,759 shs ($15K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	239,759	$0.0446	$11K
Purchase	Common Stock	96,000	$0.045	$4K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 93,629,319 shares (Direct); Common Stock — 16,780,384 shares (Indirect, By Autotelic Inc.); Common Stock — 6,872,529 shares (Indirect, By spouse)

Footnotes (1)

F1. On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446.

Key Figures

Open-market purchase 1: 96,000 shares at $0.05 Open-market purchase 2: 239,759 shares at $0.0446 Total shares bought: 335,759 shares +3 more

6 metrics

Open-market purchase 1 96,000 shares at $0.05 Common Stock bought on June 15, 2026

Open-market purchase 2 239,759 shares at $0.0446 Common Stock bought on June 17, 2026

Total shares bought 335,759 shares Net buy across two open-market transactions

Direct holdings after trades 93,629,319 shares Common Stock directly owned after June 17, 2026 purchase

Indirect holdings by spouse 6,872,529 shares Common Stock held indirectly by spouse as of June 15, 2026

Indirect holdings via Autotelic Inc. 16,780,384 shares Common Stock held indirectly through Autotelic Inc. as of June 15, 2026

Key Terms

open-market purchase, indirect ownership, beneficial ownership, Form 4

4 terms

open-market purchase financial

"purchased 96,000 shares ... from the open market at a price of $0.05"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"direct_or_indirect: "I", nature_of_ownership: "By spouse""

beneficial ownership financial

"filing lists indirect holdings ... by spouse and by Autotelic Inc."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Oncotelic (OTLC) report for CEO Vuong Trieu?

Oncotelic reported that CEO Vuong Trieu made two open-market stock purchases, totaling 335,759 common shares. These buys occurred on June 15, 2026 and June 17, 2026, reflecting additional direct investment in the company’s equity.

How many Oncotelic (OTLC) shares did the CEO buy and at what prices?

Vuong Trieu purchased 96,000 shares at $0.05 per share on June 15, 2026 and 239,759 shares at $0.0446 per share on June 17, 2026. Both were open-market purchases of common stock.

What are Vuong Trieu’s direct Oncotelic (OTLC) shareholdings after these trades?

Following the reported open-market purchases, Vuong Trieu’s directly held position in Oncotelic common stock is 93,629,319 shares. This figure comes from the post-transaction ownership column associated with his most recent reported purchase transaction.

Were the Oncotelic (OTLC) CEO’s transactions open-market purchases?

Yes. The Form 4 classifies both transactions as open-market purchases of common stock, with transaction code “P” and footnote disclosure stating they were bought from the open market at per-share prices of $0.05 and $0.0446.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/17/2026 - 07:34 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trieu Vuong

(Last)

(First)

(Middle)

29397 AGOURA RD SUITE 107

(Street)

AGOURA HILLS

CALIFORNIA

91301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncotelic Therapeutics, Inc. [ OTLC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CHAIRMAN AND CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/17/2026⁽¹⁾	06/17/2026⁽¹⁾	P		239,759	A	$0.0446	93,629,319	D
Common Stock	06/15/2026	06/15/2026	P		96,000	A	$0.045	93,389,560	D
Common Stock								16,780,384	I	By Autotelic Inc.
Common Stock								6,872,529	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446.

	/s/ Vuong Trieu	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR